<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="69558"><DrugName>RNS-60 (inhaled, asthma/amytrophic lateral sclerosis), Revalesio</DrugName><DrugSynonyms><Name><Value>ion channel modulator (asthma/inflammatory lung/Alzheimers/Parkinsons diseases/multiple sclerosis), Revalesio</Value></Name><Name><Value>RNS-60</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RNS-60 (inhaled, asthma/amytrophic lateral sclerosis), Revalesio</Value></Name></DrugSynonyms><CompanyOriginator id="1039107">Revalesio Corp</CompanyOriginator><CompaniesPrimary><Company id="1039107">Revalesio Corp</Company></CompaniesPrimary><CrossReferences><SourceEntity id="69558" type="Drug"><TargetEntity id="730251" type="siDrug">RNS-60</TargetEntity></SourceEntity><SourceEntity id="1039107" type="Company"><TargetEntity id="5035525453" type="organizationId">Revalesio Corp</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="212" type="ciIndication"><TargetEntity id="G12.2" type="ICD10"></TargetEntity><TargetEntity id="10028003" type="MEDDRA"></TargetEntity><TargetEntity id="D016472" type="MeSH"></TargetEntity><TargetEntity id="1290" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"></TargetEntity><TargetEntity id="10028245" type="MEDDRA"></TargetEntity><TargetEntity id="D009103" type="MeSH"></TargetEntity><TargetEntity id="-1241225595" type="omicsDisease"></TargetEntity><TargetEntity id="112" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"></TargetEntity><TargetEntity id="10061536" type="MEDDRA"></TargetEntity><TargetEntity id="D010300" type="MeSH"></TargetEntity><TargetEntity id="-342157116" type="omicsDisease"></TargetEntity><TargetEntity id="127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="646" type="ciIndication"><TargetEntity id="2881" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1590" type="Action"><TargetEntity id="1063" type="Mechanism">Apoptosis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity></SourceEntity><SourceEntity id="3101" type="Action"><TargetEntity id="992" type="Mechanism">Chemokine CCR3 Antagonists</TargetEntity><TargetEntity id="2897" type="Mechanism">Anti-CCR3</TargetEntity></SourceEntity><SourceEntity id="225" type="Action"><TargetEntity id="659" type="Mechanism">IL-4 Receptor Antagonists</TargetEntity><TargetEntity id="3324" type="Mechanism">Anti-IL4R</TargetEntity><TargetEntity id="2480" type="Mechanism">IL-4 Antagonists</TargetEntity></SourceEntity><SourceEntity id="17389" type="Action"><TargetEntity id="2430" type="Mechanism">Anti-CCL11 (Eotaxin-1)</TargetEntity></SourceEntity><SourceEntity id="2420" type="Action"><TargetEntity id="3654" type="Mechanism">Drugs Targeting Beta-Amyloid</TargetEntity></SourceEntity><SourceEntity id="PTGT-00352" type="ciTarget"><TargetEntity id="156700847812323" type="siTarget">C-C chemokine receptor type 3</TargetEntity><TargetEntity id="113" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00985" type="ciTarget"><TargetEntity id="55611" type="siTarget">IL-4 receptor</TargetEntity></SourceEntity><SourceEntity id="PTGT-00987" type="ciTarget"><TargetEntity id="56621" type="siTarget">IL-6 receptor</TargetEntity></SourceEntity><SourceEntity id="PTGT-04303" type="ciTarget"><TargetEntity id="196931422363563" type="siTarget">Eotaxin</TargetEntity><TargetEntity id="958" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="14">Alzheimers disease</Indication><Indication id="212">Motor neurone disease</Indication><Indication id="213">Multiple sclerosis</Indication><Indication id="255">Parkinsons disease</Indication><Indication id="646">Lung inflammation</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="511">TNF antagonist</Action><Action id="225">IL-4 receptor antagonist</Action><Action id="9422">Unspecified ion channel modulator</Action><Action id="2420">Beta amyloid modulator</Action><Action id="471">IL-6 receptor antagonist</Action><Action id="17389">Eotaxin ligand inhibitor</Action><Action id="3101">CCR3 chemokine antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="646">Bronchodilator</Action><Action id="2953">Anti-inflammatory</Action><Action id="2947">Antiparkinsonian</Action><Action id="1615">Neuroprotectant</Action><Action id="1590">Apoptosis inhibitor</Action><Action id="4945">IL-8 release inhibitor</Action></ActionsSecondary><Technologies><Technology id="1668">Nanoparticle formulation</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3A</Code><Name>ANTI-EPILEPTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-12T10:12:03.000Z</LastModificationDate><ChangeDateLast>2019-01-14T00:00:00.000Z</ChangeDateLast><AddedDate>2011-01-04T09:46:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1039107" linkType="Company"&gt;Revalesio&lt;/ulink&gt; is investigating RNS-60, an anti-inflammatory charge-stabilized nanostructure  that acts on voltage-gated ion channels, comprising an electrokinetically altered saline solution containing an elevated dissolved oxygen concentration, as an inhalant formulation for the potential treatment of amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and inflammatory lung diseases    [&lt;ulink linkID="1158481" linkType="Reference"&gt;1158481&lt;/ulink&gt;], [&lt;ulink linkID="1172709" linkType="Reference"&gt;1172709&lt;/ulink&gt;], [&lt;ulink linkID="1884926" linkType="Reference"&gt;1884926&lt;/ulink&gt;], [&lt;ulink linkID="1158306" linkType="Reference"&gt;1158306&lt;/ulink&gt;].   In December 2016, Revalesio planned  to initiate a phase II trial  of nebulized RNS-60 in patients   with ALS; in April 2017, the trial was expected to start in January 2019; in January 2019, the trial was expected to start in July 2019  [&lt;ulink linkID="1884926" linkType="Reference"&gt;1884926&lt;/ulink&gt;]. A pilot, investigator-led, phase I trial in ALS began in October 2015 [&lt;ulink linkID="1946542" linkType="Reference"&gt;1946542&lt;/ulink&gt;]. In January 2011, the company was seeking to outlicense the drug  [&lt;ulink linkID="1158481" linkType="Reference"&gt;1158481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was previously developing RNS-60 for the potential treatment of asthma. In May 2015, a   phase IIa trial for   asthma was initiated [&lt;ulink linkID="1654430" linkType="Reference"&gt;1654430&lt;/ulink&gt;]. However, no further development has been reported since May  2017.&lt;/para&gt;&lt;para&gt;The company is also developing an &lt;ulink linkID="70516" linkType="Drug"&gt;iv formulation of RNS-60&lt;/ulink&gt; for myocardial infarction and multiple sclerosis. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2019,  the US FDA granted the product Fast Track designation for treatment of ALS [&lt;ulink linkID="2109359" linkType="Reference"&gt;2109359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2017, the US FDA granted the product Orphan designation for treatment of ALS [&lt;ulink linkID="1946529" linkType="Reference"&gt;1946529&lt;/ulink&gt;], [&lt;ulink linkID="1964092" linkType="Reference"&gt;1964092&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Amyotrophic lateral sclerosis&lt;/subtitle&gt;In December 2016,  the US FDA accepted an IND application submitted by Revalesio for phase II  testing of RNS-60 in patients with ALS [&lt;ulink linkID="1903146" linkType="Reference"&gt;1903146&lt;/ulink&gt;]. At that time, a randomized,  interventional,  parallel-assignment, double-blind, phase II trial (&lt;ulink linkID="281739" linkType="Protocol"&gt;NCT02988297&lt;/ulink&gt;; 06.2.1.H6) of nebulized RNS-60 was planned to be initiated in patients (expected n = 140) with ALS in January 2018 and to complete in January 2021 [&lt;ulink linkID="1884926" linkType="Reference"&gt;1884926&lt;/ulink&gt;]. At that time, enrollment of patients was expected to begin in March 2017 [&lt;ulink linkID="1903146" linkType="Reference"&gt;1903146&lt;/ulink&gt;]. In April 2017, the trial was expected to start in January 2019 [&lt;ulink linkID="1884926" linkType="Reference"&gt;1884926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, an interventional, randomized, parallel assignment, multicenter, double-blind, placebo-controlled, parallel group, add-on phase II trial (&lt;ulink linkID="331702" linkType="Protocol"&gt;NCT03456882&lt;/ulink&gt;; RNS60)led by &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; and funded by the ALS Therapy Fund was initiated in the US and Italy in patients (expected n = 142) with ALS. The trial was expected to complete in April 2019 [&lt;ulink linkID="2109828" linkType="Reference"&gt;2109828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, an investigator-sponsored, placebo-controlled, multicenter, phase II study, with funding from the ALS Association and ALS Finding a Cure, was expected to start recruiting as early as March of 2017 [&lt;ulink linkID="1903146" linkType="Reference"&gt;1903146&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, a pilot, phase I trial (&lt;ulink linkID="237488" linkType="Protocol"&gt;NCT02525471&lt;/ulink&gt;; RNS60-01), led by &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; and funded by the ALS Therapy Fund, was initiated to investigate the safety and tolerability of RNS-60, administered by iv infusion and inhalation, in patients (n = 18) with ALS. The study would also evaluate the impact of RNS-60 on markers of neuro-inflammation, measured by blood biomarkers and PET imaging. In April 2017, the trial was ongoing but no longer recruiting and was expected to complete in March 2018 [&lt;ulink linkID="1946542" linkType="Reference"&gt;1946542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Parkinson's disease&lt;/subtitle&gt;In December 2014, protocol development for an exploratory efficacy study in PD patients was underway [&lt;ulink linkID="1623075" linkType="Reference"&gt;1623075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alzheimer's disease&lt;/subtitle&gt;In January 2011, clinical trial protocol development for AD was ongoing [&lt;ulink linkID="1158481" linkType="Reference"&gt;1158481&lt;/ulink&gt;]. In December 2014, this was still the case [&lt;ulink linkID="1623075" linkType="Reference"&gt;1623075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asthma&lt;/subtitle&gt;In April 2015, a randomized, double-blind, placebo controlled, cross over phase IIa study (&lt;ulink linkID="227580" linkType="Protocol"&gt;NCT02422121&lt;/ulink&gt;; 01.1.1.H3) was planned to be initiated in the UK, in May 2015, to evaluate the effects of multiple doses of RNS-60 and &lt;ulink linkID="51851" linkType="Drug"&gt;budesonide&lt;/ulink&gt; in patients (expected n = 18) with mild asthma. At that time, the study was expected to complete in November 2015. In May 2015, the trial was initiated [&lt;ulink linkID="1654430" linkType="Reference"&gt;1654430&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, clinical trial protocol development was ongoing to initiate a phase II trial in asthma [&lt;ulink linkID="1543248" linkType="Reference"&gt;1543248&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, a study to evaluate the efficacy of nebulized RNS-60 to treat asthma symptoms after an allergen challenge was planned to be initiated in the first quarter of 2015, in the UK [&lt;ulink linkID="1623075" linkType="Reference"&gt;1623075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2014, an allergen challenge study was underway in the US, to evaluate the effect of RNS-60 on regional inflammation and bronchoconstriction in the lung [&lt;ulink linkID="1623075" linkType="Reference"&gt;1623075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, the company received approval of an IND for a phase I/IIa trial in  healthy subjects and  in subjects with mild to moderate asthma in combination with budesonide. The trial would be conducted in collaboration with &lt;ulink linkID="20679" linkType="Company"&gt;Stanford University&lt;/ulink&gt; and West Coast Clinical Trials  [&lt;ulink linkID="1158306" linkType="Reference"&gt;1158306&lt;/ulink&gt;]. The trial began later in May 2010 and was expected to complete in January 2011 [&lt;ulink linkID="1158307" linkType="Reference"&gt;1158307&lt;/ulink&gt;]. In August 2010, results from the 20-subject phase I portion of the trial showed no toxicity or adverse events had been reported. The next phase of the trial would enroll 75 patients [&lt;ulink linkID="1158308" linkType="Reference"&gt;1158308&lt;/ulink&gt;]. By March 2011,  the 28-day, multi-dose inhalation, phase II portion of  the phase I/IIa study  had been  planned  [&lt;ulink linkID="1172709" linkType="Reference"&gt;1172709&lt;/ulink&gt;]. In October 2011, data from the multi-dose stage of the phase I study were reported. RNS-60 showed a therapeutic benefit and was safe at all the doses. Significant improvement was observed in peak flows and quality of life scores in patients. Safety and efficacy data were expected to be presented     at the American College of Allergy, Asthma and Immunology meeting in Boston, MA, in November, 2011. By that time, the phase II portion of the study had been initiated to evaluate RNS-60 in combination with high and low dose budesonide [&lt;ulink linkID="1235408" linkType="Reference"&gt;1235408&lt;/ulink&gt;].  In March 2014, clinical data were presented at the 2014 Annual AAAAI Meeting in San Diego, CA. RNS-60 in combination with high- and low-dose budesonide was safe and effective and there were no significant differences in FEV1 between groups. Low-dose budesonide with RNS-60 was as effective as  the combination of high-dose budesonide and saline [&lt;ulink linkID="1522176" linkType="Reference"&gt;1522176&lt;/ulink&gt;]; later that month, additional data were presented at the conference which demonstrated that the drug was well tolerated. At that time, preparation was underway to publish the results  later in  2014 [&lt;ulink linkID="1543248" linkType="Reference"&gt;1543248&lt;/ulink&gt;]. In May 2015, further clinical data were presented at the 2015 ATS International Conference in Denver, CO.										High-budesonide and low-budesonide + RNS-60 treatment showed similar improvement in  quality of life. The combination of RNS-60 with low dose corticosteroids resulted in similar effects, as that of high dose inhaled corticosteroids [&lt;ulink linkID="1679450" linkType="Reference"&gt;1679450&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Early studies&lt;/subtitle&gt;By January 2013, the drug had demonstrated an excellent safety profile, without any side effects, in two phase I trials [&lt;ulink linkID="1353979" linkType="Reference"&gt;1353979&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2018, preclinical data were presented at the Annual Conference of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in  San Diego, data demonsterated that RNS-60 stimulated the expression of myelin-specific genes and proteins  in primary mouse oligodendroglia and mixed glial cells, RNS60 treatment induced the activation of cAMP response element binding protein (CREB) in oligodendrocytes, ultimately leading to the recruitment of CREB to the promoters of myelin-specific genes [&lt;ulink linkID="2011599" linkType="Reference"&gt;2011599&lt;/ulink&gt;], [&lt;ulink linkID="2011481" linkType="Reference"&gt;2011481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, data were published demonstrating increased formation of mitochondria and increased ATP production in neuronal cells treated with RNS-60. This effect was seen both in a dopaminergic neuronal cell line and in the brain of RNS-60-treated mice and it was mediated through increased expression of PGC-1, a key gene associated with mitochondrial biogenesis [&lt;ulink linkID="2002595" linkType="Reference"&gt;2002595&lt;/ulink&gt;], [&lt;ulink linkID="2002938" linkType="Reference"&gt;2002938&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, preclinical data from murine studies were published demonstrated that inhalation of nebulized RNS-60 produced favorable effects similar to injectable &lt;ulink linkID="70516" linkType="Drug"&gt; RNS-60&lt;/ulink&gt; in a model of MS, which involved reduced paralysis and a protection of the myelin coating of neurons in the brain. Also, the drug had inhibited perivascular cuffing, maintained the integrity of blood–brain and blood–spinal cord barriers, suppressed inflammation, normalized the expression of myelin genes, and blocked demyelination in the CNS to experimental allergic encephalomyelitis mice. Enrichment of anti-autoimmune regulatory T cells (Tregs) and suppression of autoimmune Th17 cells were observed. This pioneer research proved the prospect of utilizing the inhaled therapeutic, where repeated injections was not a feasible option [&lt;ulink linkID="1916680" linkType="Reference"&gt;1916680&lt;/ulink&gt;], [&lt;ulink linkID="1916717" linkType="Reference"&gt;1916717&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were presented at the 46th SFN Annual Meeting in San Diego, CA. Learning ability of APP/PS1 transgenic mice was found to be improved with intraperitoneal administration of RNS-60, whereas, whole brain uptake of 18F-GE180 was decreased along with reduction in amyloid beta 42, microglia activation and macrophase [&lt;ulink linkID="1871184" linkType="Reference"&gt;1871184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, preclinical data were published. Data demonstarted that RNS-60 helped oligodendrocytes survive and mature by influencing their bioenergetics [&lt;ulink linkID="2011481" linkType="Reference"&gt;2011481&lt;/ulink&gt;], [&lt;ulink linkID="2011800" linkType="Reference"&gt;2011800&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, preclinical data were presented at the 2016 AAIC in Toronto, Canada. In aged APPSWE/PS1dE9 mice, RNS-60 showed no effect on locomotor activity and learning/memory in open field and water T-maze test, respectively.. RNS-60 showed increase in anti-inflammatory cytokines and decrease in pro-inflammatory cytokines in APP-PS1 transgenic mice. Treatment with RNS-60 resulted in increase of synaptic puncta density, synaptic protein, mature-brain-derived neurotrophic factor and decreased GSK3beta activity in transgenic mice [&lt;ulink linkID="1782070" linkType="Reference"&gt;1782070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 68th AAN Annual Meeting in Vancouver, Canada. In November 2014, preclinical data were presented at the 44th SFN Meeting in Washington, DC. In 5XFAD transgenic mouse model of AD, RNS-60 attenuated neuronal apoptosis and tau phosphorylation in hippocampus and protected memory and learning. In neuronal cells, RNS-60 prevented fibrillar alphabeta-induced apoptosis, cell death and tau phosphorylation [&lt;ulink linkID="1609535" linkType="Reference"&gt;1609535&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. Nebulized RNS-60 suppressed the infiltration of mononuclear cells in the spinal cord. In spinal cord of EAE mice, nebulized RNS-60 inhibited demyelination. Suppression of ROR-gamma-t, transcription factor for Th17 cell differentiation was demonstrated by nebulized RNS-60 in female mice [&lt;ulink linkID="1753746" linkType="Reference"&gt;1753746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 66th AAN Annual Meeting in Philadelphia, PA.  In cultured mouse hippocampal neurons, RNS-60 (10% for 5, 15 or 30 min) stimulated NMDA- and AMPA-dependent calcium influx and induced morphological plasticity. In vivo, RNS-60 increased the expression of plasticity-associated proteins in the hippocampus of 5XFAD transgenic mice [&lt;ulink linkID="1544887" linkType="Reference"&gt;1544887&lt;/ulink&gt;]. In October 2014, similar data were published [&lt;ulink linkID="1603802" linkType="Reference"&gt;1603802&lt;/ulink&gt;], [&lt;ulink linkID="1603767" linkType="Reference"&gt;1603767&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, preclinical data were published and demonstrated that RNS-60 with artificial seawater (ASW) enhanced the natural synaptic function of squid neurons and elicited a larger postsynaptic signal compared to synapses treated with control (ASW alone). Also, RNS-60 treated synapses showed an increase in spontaneous transmitter release with modified noise kinetics and were within the normal physiological boundaries  [&lt;ulink linkID="1524877" linkType="Reference"&gt;1524877&lt;/ulink&gt;], [&lt;ulink linkID="1524680" linkType="Reference"&gt;1524680&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, data were presented at the Alzheimer's Association International Conference 2013 in Boston, MA. In neuronal cells and transgenic 5XFAD mouse models, RNS-60 was found to attenuate apoptosis and amyloid-beta (1 to 42)-mediated tau phosphorylation via activation of PI3k-Akt pathway. In  5XFAD mice, RNS-60 improved learning and memory while decreased the levels of activated NFkappaB and IL-1-beta [&lt;ulink linkID="1453919" linkType="Reference"&gt;1453919&lt;/ulink&gt;], [&lt;ulink linkID="1452719" linkType="Reference"&gt;1452719&lt;/ulink&gt;]. In October 2014, similar data were published [&lt;ulink linkID="1603796" linkType="Reference"&gt;1603796&lt;/ulink&gt;], [&lt;ulink linkID="1603767" linkType="Reference"&gt;1603767&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, &lt;ulink linkID="23269" linkType="Company"&gt;NYU Langone Medical Center&lt;/ulink&gt; was conducting research to define the activity of RNS-60 on synaptic function and neuronal health. The research would build on previous studies at &lt;ulink linkID="1009311" linkType="Company"&gt;Rush University Medical Center&lt;/ulink&gt; demonstrating the antiinflammatory and neuroprotective activity of RNS-60 in cellular assays and preclinical animal models [&lt;ulink linkID="1452891" linkType="Reference"&gt;1452891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 2013 ISN-ASN joint conference in Cancun, Mexico. Administration of RNS-60 at 5-month old transgenic mouse model of AD showed improved learning and prevented memory loss. The drug also showed significant reduction in levels of cellular markers associated with AD. The results were indistinguishable from those of non-transgenic mice (wild-type) and the untreated mice developed severe functional memory and learning loss. At that time, the company planned to prepare a manuscript of recent findings for publication in a scientific journal [&lt;ulink linkID="1413205" linkType="Reference"&gt;1413205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, data were presented at the 65th AAN Annual Meeting in San Diego, CA.  In female SJL/J mice, single injection of RNS-60-induced Tregs,  resulting in significant amelioration of clinical symptoms of relapse-remitting autoimmune encephalomyelitis. CD25 antibody was found to abrogate the therapeutic effects of RNS-60 confirming that the Tregs mediate the protective effect of RNS-60   [&lt;ulink linkID="1389419" linkType="Reference"&gt;1389419&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, data were published. In a mouse model of MS, RNS-60 was found to halt disease progression, prevent inflammation in the brain and spinal column, and protect against demyelination. The drug protected infiltration of inflammatory cells to the central nervous system and thus, preserved myelin. RNS-60 increased the proportion of regulatory T cells and reduced the number of inflammatory Th17 T-cells. RNS-60 also inhibited encephalitogenicity of MBP-primed T cells [&lt;ulink linkID="1354157" linkType="Reference"&gt;1354157&lt;/ulink&gt;], [&lt;ulink linkID="1353979" linkType="Reference"&gt;1353979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, preclinical data were presented at the 42nd Annual SFN Meeting in New Orleans, LA. In familial Alzheimer's disease 5X transgenic mice, RNS-60 significantly inhibited the memory impairment and reduced the  proinflammatory markers  when compared with the normal saline-treated or untreated transgenic mice groups [&lt;ulink linkID="1330659" linkType="Reference"&gt;1330659&lt;/ulink&gt;]. At that time, data also demonstrated that injection of RNS-60 reduced the activation of glial cells in the brains of mice [&lt;ulink linkID="1338385" linkType="Reference"&gt;1338385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, data from a study conducted in a rodent model of MS were  presented at The American Society for Neurochemistry Annual Conference (ASN) in Baltimore, Maryland demonstrating RNS-60 increased the relative proportion of T-regulatory cells and shifted the immune response from a Th17 and Th1 type to a Th2 type lymph node cells [&lt;ulink linkID="1269501" linkType="Reference"&gt;1269501&lt;/ulink&gt;]. In April 2012, further preclinical data were presented at the 64th AAN Annual Meeting in New Orleans, LA from a mouse study. Results suggested that RNS-60 significantly altered disease progression in the model through immune modulation [&lt;ulink linkID="1284873" linkType="Reference"&gt;1284873&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2012, data from treatments for neuro-inflammatory disease were presented at ASN in Baltimore, Maryland demonstrating RNS-60 inhibited the production of inflammatory proteins and chemicals in glial cells mediated through production of IkBalpha protein [&lt;ulink linkID="1269501" linkType="Reference"&gt;1269501&lt;/ulink&gt;]. In April 2012, similar preclinical data were presented at the 64th AAN Annual Meeting in New Orleans, LA. RNS-60's ability to prevent nigrostriatal degeneration in the MPTP mouse model of Parkinson's disease (PD) was also assessed [&lt;ulink linkID="1284875" linkType="Reference"&gt;1284875&lt;/ulink&gt;]. In October 2013, data were published. Data demonstrated that RNS-60 significantly enhanced biochemical and behavioral (movement) outcomes in a mouse model of PD. The drug also preserved the motor function of the animals [&lt;ulink linkID="1488619" linkType="Reference"&gt;1488619&lt;/ulink&gt;], [&lt;ulink linkID="1488436" linkType="Reference"&gt;1488436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented demonstrating RNS-60 to significantly reduce disease scores in multiple preclinical models of MS. The drug also dose-dependently inhibited activation of Tau in a cell culture model of Alzheimer's disease and to protect neurons challenged with beta-amyloid from apoptosis. At that time, similar data were to be presented later that month at the American Academy of Neurology meeting in Honolulu, HI [&lt;ulink linkID="1181718" linkType="Reference"&gt;1181718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, preclinical data were to be presented at the Annual Meeting of the American Academy of Allergy Asthma and Immunology in San Francisco, CA later that month. In a preclinical asthma model, RNS-60 improved respiratory parameters compared with budesonide and significantly reduced inflammatory cytokines, such as IL-6, IL-4, TNF-alpha and eotaxin. In cell culture studies the drug decreased the production of CCR3 and IL-8 [&lt;ulink linkID="1177269" linkType="Reference"&gt;1177269&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By March 2011,  data from studies on RNS-60 in PD and AD models had shown  neuroprotective effects and significant improvements in the survival of neurons, preservation of motor skills and motor-dependent behaviors [&lt;ulink linkID="1172709" linkType="Reference"&gt;1172709&lt;/ulink&gt;]. Further data reported later that month at the American Society of Neurochemistry meeting in St Louis, MO, showed that RNS-60 protected cultured cells against beta-amyloid induced  cell death. At that time, data showing the ability of the drug to prevent tau hyperphosphorylation were to be presented at the American Academy of Neurology meeting in Honolulu, HI, in April 2010. At the same meeting, data showing that the drug protected neurons, restored dopamine levels and improved motor function in a mouse model of Parkinson's disease were also to be reported [&lt;ulink linkID="1176370" linkType="Reference"&gt;1176370&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, in vivo studies in AD models were ongoing [&lt;ulink linkID="1158481" linkType="Reference"&gt;1158481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2011, preclinical data from the ovalbumin challenge model in rats had shown animals treated with RNS-60 had a 3-fold improvement in  tidal volume and also showed significant downregulation of inflammatory cytokines and chemokines in  blood and  bronchoalveolar lavage fluid 24 h after the asthma challenge. The compound had also shown therapeutic efficacy with  a significant absence of toxicity. In neuronal cells, RNS-60 was shown to target pathways  involved in cell death and hyperphosphorylation of tau [&lt;ulink linkID="1158481" linkType="Reference"&gt;1158481&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="646">Lung inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-04T00:00:00.000Z</StatusDate><Source id="1158481" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-04T00:00:00.000Z</StatusDate><Source id="1158481" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-04T00:00:00.000Z</StatusDate><Source id="1158481" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-08T00:00:00.000Z</StatusDate><Source id="1884926" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-01-04T00:00:00.000Z</StatusDate><Source id="1158481" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-11-19T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1039107">Revalesio Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-05-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1039107">Revalesio Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-29T00:00:00.000Z</StatusDate><Source id="1623075" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-19T00:00:00.000Z</StatusDate><Source id="1158307" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1039107">Revalesio Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-07T00:00:00.000Z</StatusDate><Source id="1654430" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1039107">Revalesio Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-05-07T00:00:00.000Z</StatusDate><Source id="1158306" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1039107">Revalesio Corp</OwnerCompany><Country id="US">US</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis (ALS)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-04T00:00:00.000Z</MileStoneDate><Source id="2109359" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1039107">Revalesio Corp</OwnerCompany><Country id="US">US</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis (ALS)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-10T00:00:00.000Z</MileStoneDate><Source id="1946542" type="TRIALREG"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00134"><Name>Beta amyloid</Name><SwissprotNumbers><Swissprot>O73683</Swissprot><Swissprot>O93279</Swissprot><Swissprot>P05067</Swissprot><Swissprot>P08592</Swissprot><Swissprot>P12023</Swissprot><Swissprot>P14599</Swissprot><Swissprot>P29216</Swissprot><Swissprot>P53601</Swissprot><Swissprot>P79307</Swissprot><Swissprot>Q10651</Swissprot><Swissprot>Q28053</Swissprot><Swissprot>Q28280</Swissprot><Swissprot>Q28748</Swissprot><Swissprot>Q28757</Swissprot><Swissprot>Q29149</Swissprot><Swissprot>Q5IS80</Swissprot><Swissprot>Q60495</Swissprot><Swissprot>Q95241</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00352"><Name>CCR3 chemokine</Name><SwissprotNumbers><Swissprot>O54814</Swissprot><Swissprot>P51677</Swissprot><Swissprot>P51678</Swissprot><Swissprot>P56483</Swissprot><Swissprot>P56492</Swissprot><Swissprot>Q64H34</Swissprot><Swissprot>Q9BDS8</Swissprot><Swissprot>Q9Z2I3</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00985"><Name>IL-4 receptor</Name><SwissprotNumbers><Swissprot>P16382</Swissprot><Swissprot>P24394</Swissprot><Swissprot>Q63257</Swissprot><Swissprot>Q6WG24</Swissprot><Swissprot>Q863Z5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00987"><Name>IL-6 receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-01874"><Name>TNF receptor</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-02157"><Name>Unspecified ion channel</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-04303"><Name>Eotaxin ligand</Name><SwissprotNumbers><Swissprot>P48298</Swissprot><Swissprot>P51671</Swissprot><Swissprot>P80325</Swissprot><Swissprot>P97545</Swissprot><Swissprot>Q8MIT7</Swissprot><Swissprot>Q9TTQ4</Swissprot><Swissprot>Q9TTS6</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009311">Rush University Medical Center</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1039107">Revalesio Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20646">New York University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="143352" title="Revalesio and Rush University to collaborate on the development of RNS-60 for multiple sclerosis"></Deal><Deal id="145923" title="NYU Langone Medical Center to collaborate on research of Revalesio's RNS-60 for Alzheimer's disease"></Deal></Deals><PatentFamilies><PatentFamily id="1932881" number="WO-2012142501" title="Compositions and methods for inhibiting and/or modulating effector T-cells involved in inflammatory neurodegenerative disease"></PatentFamily><PatentFamily id="2154946" number="WO-2012021856" title="Compositions and methods for treatment of taupathy"></PatentFamily><PatentFamily id="2475792" number="WO-2009134728" title="Compositions and methods for treating multiple sclerosis"></PatentFamily><PatentFamily id="2487089" number="WO-2009134929" title="Compositions and methods for treating digestive disorders"></PatentFamily><PatentFamily id="2487106" number="WO-2011137317" title="Methods and compositions for protecting against neurotoxic agents"></PatentFamily><PatentFamily id="2600058" number="WO-2008052143" title="Mixing device and output fluids of same"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Revalesio Corp" id="1039107"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>